Cargando…
Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds
Entamoeba histolytica is a protozoan parasite which infects approximately 50 million people worldwide, resulting in an estimated 70,000 deaths every year. Since the 1960s E. histolytica infection has been successfully treated with metronidazole. However, drawbacks to metronidazole therapy exist, inc...
Autores principales: | Sauvey, Conall, Ehrenkaufer, Gretchen, Shi, Da, Debnath, Anjan, Abagyan, Ruben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895358/ https://www.ncbi.nlm.nih.gov/pubmed/33556060 http://dx.doi.org/10.1371/journal.pntd.0008425 |
Ejemplares similares
-
High-throughput phenotypic screen identifies a new family of potent anti-amoebic compounds
por: Sauvey, Conall, et al.
Publicado: (2023) -
CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM)
por: Debnath, Anjan, et al.
Publicado: (2017) -
Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia
por: Kangussu-Marcolino, Monica M., et al.
Publicado: (2019) -
Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes
por: Ferrins, Lori, et al.
Publicado: (2023) -
Corrigendum: Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes
por: Ferrins, Lori, et al.
Publicado: (2023)